期刊文献+

多种羧化酶缺乏症15例临床分析及长期随访 被引量:17

Clinical analysis and long-term follow-up of multiple carboxylase deficiency in 15 children
原文传递
导出
摘要 目的 探讨多种羧化酶缺乏症(MCD)2种类型的临床特点、诊断与治疗方法.方法 应用气相色谱质谱(GC/MS)联用尿液有机酸分析、外周血生物素酶(BT)活性测定、BT及全羧化酶合成酶(HLCS)基因突变分析进行诊断与分型,对15例MCD患儿的临床资料进行总结分析并随诊.结果 1.MCD 15例患儿尿GC/MS分析见乳酸、3-羟基丁酸、3-羟基异戊酸,3-甲基巴豆酰甘氨酸、甲基枸橼酸及3-羟基丙酸.其中14例确诊为HLCS缺乏症,1例为BT缺乏症.2.HLCS缺乏症起病早,大多数出生后5个月内发病,14例均以反复皮疹为首发症状,伴反复气促9例,精神运动发育迟缓8例,反复呕吐5例,喂养困难3例,运动倒退、抽搐各1例.血气分析示持续性代谢性酸中毒,大部分患儿有酮尿、高乳酸血症、高尿酸血症、高氨血症、低血糖.除1例死亡外,13例给予生物素治疗,48 h内代谢紊乱纠正,随诊至今3~11(6.47 ±2.70)年,未再发,体格、智力发育正常.3.BT缺乏症1例患儿于1岁4个月起病,表现为神志改变、肢体颤抖,呼吸不规则,头颅磁共振检查提示胼胝体脱髓鞘样损害,起病第2天开始生物素治疗,随访1年,右侧肢体肌力仍未能完全恢复.结论 反复皮疹、气促、代谢紊乱是HLCS缺乏症的主要临床特征;BT缺乏症以神经系统损害更明显,常以神经系统急性脱髓鞘改变起病.GC/MS尿有机酸分析是早期诊断的重要依据.2种类型MCD早期开始生物素治疗疗效显著,长期随诊,预后良好,部分BT缺乏症治疗不及时可遗留神经系统后遗症. Objective Multiple carboxylase deficiency(MCD) is an autosomal recessively inherited defect of organic acid metabolism.The underlying mechanism is biotinidase(BT) or holocarboxylase synthetase(HLCS) deficiency.The authors reported 15 cases of MCD(clinical characteristics,diagnosis and treatment) and outcomes of long-term follow-up.Methods The clinical data of 15 patients with MCD admitted to Guangzhou Women and Children's Medical Center between Aug.2001 and Feb.2013 were analyzed.The diagnosis was confirmed by urinary organic acid analysis with gas chromatography/mass spectrometry (GC/MS),blood enzymatic determination and gene analysis.The patients consisted of 12 male and 3 female.The onset age ranged from newborn infants to 16 months.Results 1.Remarkable elevations of urinary lactate,3-oxy-butyric acid,3-OH-isovalerate,methylcitrate,3-methylcrontonylglycine,3-OH-propionate were detected in all of 15 cases.Fourteen cases with HLCS deficiency and 1 case with BT deficiency were confirmed by gene analysis.2.Most of patients with HLCS deficiency presented in the neonatal period or early infancy.The main clinical manifestations were skin rash (14 cases),tachypnea (9 cases),developmental retardation (8 cases),vomiting(5 cases),poor feeding (3 cases),developmental regradation (1 case),convulsion (1 case).Laboratory evaluation showed persistent metabolic acidosis and varied degree of ketosis,lactic acidosis,hyperuricacidemia,ammoniemia and hypoglycemia.Biotin was given to 13 patients in 10 mg/d and their metabolic disorders were corrected within 48 h,except one who gave up treatment and died.Treatment with Biotin in 5 mg/d provided clinical stability and normal neurodevelopmental outcome on follow-up for 3-11 (6.47 ± 2.70) years.3.One patient with BT deficiency presented with severe neurological symptoms(impaired consciousness,limbs trembling,tachypnea with irregular respiratory rhythm) at 16 months old.Demyelination of corpus callosum was evident on magnetic resonance imaging.Biotin treatment was given to him on the second of onset,and 1-year follow-up indicated significant improvement of his clinical symptoms,but the right limb weakness did not completely recover.Conclusions The main clinical features of HLCS deficiency include frequent skin rash,tachypnea,and metabolic disorders.BT deficiency may produce variable neurologic manifestations including demyelination of corpus callosum.Urinary organic acid analysis with GC/MS is critical to the early diagnosis of MCD.Prompt biotin treatment is recommended to correct metabolic derangements and continued therapy is essential to the improvement of long-term prognosis.Delayed commencement of therapy in BT deficiency can result in irreversible neurological damage.
出处 《中华实用儿科临床杂志》 CAS CSCD 北大核心 2014年第8期590-594,共5页 Chinese Journal of Applied Clinical Pediatrics
基金 基金项目:“十一五”国家科技支撑计划项目(2006BA105A07) 国家科技计划课题(2012BA109804) 广州市科信局重大民生专项(2010J-E231-1)
关键词 多种羧化酶缺乏 生物素酶 全羧化酶合成酶 生物素 Multiple carboxylase deficiency Biotinidase Holocarboxylase synthetase Biotin
  • 相关文献

参考文献20

  • 1Wolf B. Disorders of biotin metabolism[A].New York:McGraw-Hill,2001.3935-3962.
  • 2李端,刘丽,李秀珍,程静,赵小媛,周荣.中国人多种羧化酶缺陷症患儿4例及其父母基因突变分析[J].中华儿科杂志,2006,44(11):865-868. 被引量:6
  • 3Cowan TM,Blitzer MG,Wolf B. Working Group of the American College of Medical Genetics(ACMG) Laboratory Quality Assurance Committee.Technical standards and guidelines for the diagnosis of biotinidase deficiency[J].GENETICS IN MEDICINE,2010,(07):464-470.
  • 4Rios-Avila L,Prince SA,Wijeratne SS. A 96-well plate assay for high-throughput analysis of holocarboxylase synthetase activity[J].Clinica Chimica Acta,2011,(9-10):735-739.
  • 5Bao B,Pestinger V,Hassan YI. Holocarboxylase synthetase is a chromatin protein and interacts directly with histone H3 to mediate biotinylation of K9 and K18[J].Journal of Nutritional Biochemistry,2011,(05):470-475.
  • 6Zempleni J,Hassan YI,Wijeratne SS. Biotin and biotinidase deficiency[J].Expert Review of Endocrinology & Metabolism,2008,(06):715-724.
  • 7Tang NL,Hui J,Yong CK. A genomic approach to mutation analysis of holocarboxylase synthetase gene in three Chinese patients with late onset holocarboxylase synthetase deficiency[J].CLINICAL BIOCHEMISTRY,2003,(02):145-149.
  • 8方伯梁(译),钱素云(校).儿童严重脓毒症流行病学趋势[J].中国小儿急救医学,2013,20(5):467-467. 被引量:1
  • 9Hayati AA,Wan-Hitam WH,Cheong MT. Optic neuritis in a child with biotinidase deficiency:case report and literature review[J].Clinical Ophthalmology,2012.389-395.
  • 10Komur M,Okuyaz C,Ezgu F. A girl with spastic tetraparesis associated with biotinidase deficiency[J].European Journal of Neurology,2011,(06):551-553.

二级参考文献8

  • 1Wolf B,Heard GS.Screening for biotinidase deficiency in newborns:worldwide experience.Pediatrics,1990,85:512-517.
  • 2Aoki Y,Suzuki Y,Sakamoto O,et al.Molecular analysis of holocarboxylase synthetase deficiency:a missense mutation and a single base deletion are predominant in Japanese patients.Biochim Biophys Acta,1995,1272:168-174.
  • 3Xue Y,Yoko A,Xue L,et al.Haplotype analysis suggests that the two predominant mutations in Japanese patients with holocarboxylase synthetase deficiency are founder mutations.J Hum Genet,2000,45:358-362.
  • 4Tang NL,Hui J,Yong CK,et al.A genomic approach to mutation analysis of holocarboxylase synthetase gene in three Chinese patients with late-onset holocarboxylase synthetase deficiency.Clin Biochem,2003,36:145-149.
  • 5Hwu WL,Suzuki Y,Yang X,et al.Late-onset holocarboxylase synthetase deficiency with homologous R508W mutation.J Formos Med Assoc,2000,99:174-177.
  • 6Dupuis L,Campeau E,Leclerc D,et al.Mechanism of biotin responsiveness in biotin-responsive multiple carboxylase deficiency.Mol Genet Metab,1999,66:80-90.
  • 7杨艳玲,山口清次,田上泰子,张月华,熊晖,长谷川有纪,木村正彦,花井润师,藤田晃三,钱宁,何晓菊,吴晔,包新华,秦炯,吴希如.生物素酶缺乏症的诊断与治疗六例分析[J].中华儿科杂志,2003,41(4):249-251. 被引量:20
  • 8杜敏联.小儿内分泌遗传代谢病诊治进展[J].中国实用儿科杂志,2004,19(5):276-277. 被引量:1

共引文献5

同被引文献40

  • 1邹丽萍,王旭.疑难病研究—生物素酶缺乏症[J].中国当代儿科杂志,2005,7(5):435-438. 被引量:10
  • 2李端,刘丽,李秀珍,程静,赵小媛,周荣.中国人多种羧化酶缺陷症患儿4例及其父母基因突变分析[J].中华儿科杂志,2006,44(11):865-868. 被引量:6
  • 3杨艳玲.生物素与生物素酶缺乏症[J].临床儿科杂志,2006,24(12):941-943. 被引量:19
  • 4石超,常建民.多羧化酶缺乏症[J].临床皮肤科杂志,2007,36(11):737-738. 被引量:3
  • 5BLAU N, BURAN M, GIBSON K M. Laboratory guide to the methods in biochemical genetics [ M ]. Berlin Heidelberg: Sprin- ger, 2008: 253.
  • 6COWAN T M, BLITZER M G, WOLF B, et al. Technical stan- dards and guidelines for the diagnosis of biotinidase deficiency [J]. Genet Med, 2010, 12(7) : 464 -470.
  • 7VENKATARAMAN V, BALAJI P, PANIGRAHI D, et al. Biotini- dase deficiency in childhood [ J]. Neurol India, 2013, 61 (4) : 411 -413.
  • 8SIVRI H S, GENG G A, TOKATLI A, et al. Hearing loss in bi- otinidase deficiency: genotype - phenotype correlation [ J ]. J Pediatr, 2007, 150(4) : 439 -442.
  • 9RAHA S, UDANI V. Biotinidase deficiency presenting as recur- rent myelopathy in a 7 - year - old boy and a review of the litera- ture[J]. Pediatr Neurol, 2011,45(4) : 261 -264.
  • 10WIZNITZER M, BANGERT B A. Biotinidase deficiency: clinical and MRI findings consistent with myelopathy[ J]. Pediatr Neurol, 2003, 29(1) : 56 -58.

引证文献17

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部